Epitope mimics for precision immunosuppression

Kairos Biotech Ltd旨在为以前难以移植的患者改善移植结果和移植等待时间。许多终末期器官衰竭患者对潜在的供体器官有抗体，这会导致移植排斥反应。这些患者等待移植的时间很长，或者可能永远不会接受移植。目前的免疫抑制方案往往针对整个免疫系统，这可能使患者容易受到感染和癌症等有害副作用的影响。Kairos Biotech正在设计新型分子“EM”，专门针对这些“抗供体”抗体和产生这些抗体的细胞。这些分子的特异性足以使抗感染抗体保持完整，从而使移植能够进行，否则无法进行。我们目前的研究重点是可以在移植前使用的分子，以去除有害抗体，或精确靶向产生抗体的细胞。这种方法有望在移植后用于持续的特异性免疫抑制。预计这些分子还将彻底改变检测和鉴定特异性抗体的方式，从而改善诊断和对抗体介导的排斥反应的理解。第一批应用预计将在诊断测试中检测移植、输血和罕见自身免疫性疾病中的破坏性抗体。使用EM靶向抗供体抗体的相同原理可以应用于治疗自身免疫性疾病，其中患者循环中的抗体可能攻击自身细胞。在抗体攻击患者体内细胞或攻击移植器官的自身免疫性疾病中，EM将能够特异性抑制那些致病抗体，而不会抑制免疫系统并使患者易于感染。

Kairos Biotech Ltd aims to improve transplantation outcomes and transplant waiting times, for previously difficult to transplant patients.Many patients with end-stage organ failure have antibodies to potential donor organs which would cause transplant rejection. These patients wait a long time for a transplant, or may never receive a transplant. Current immunosuppression regimes tend to target the whole immune system which can leave patients vulnerable to deleterious side effects such as infection and cancer.Kairos Biotech are designing novel molecules 'EMs' that specifically target these 'anti-donor' antibodies, and the cells that produce these antibodies. These molecules are specific enough to leave anti-infection antibodies intact thus allowing transplants to proceed that would otherwise not be able to.Our current research focusses on molecules that can be used pre-transplant to either remove deleterious antibodies, or precisely target cells that make the antibodies. This approach is expected to be used post-transplant for continued specific immunosuppression.It is expected that these molecules will also revolutionise the way in which specific antibodies are detected and identified leading to improvements in diagnostics and understandings of antibody-mediated rejection. The first applications are expected to be in diagnostic tests that detect damaging antibodies in transplant, blood transfusion and rare autoimmune diseases.The same principle of using EMs to target anti-donor antibodies can be applied to the treatment of autoimmune diseases where antibodies in the patient's circulation may attack their own cells. In autoimmune conditions where antibodies attack cells in the patient's body or attack transplanted organs the EMs will enable specific suppression of those disease-causing antibodies without supressing the immune system and leaving the patient prone to infection.